[go: up one dir, main page]

NO20090137L - Fremgangsmate for fremstilling av N-hydroksy-3-[4-[[[2-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]-2E-2-propenamid og startmaterialer derav - Google Patents

Fremgangsmate for fremstilling av N-hydroksy-3-[4-[[[2-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]-2E-2-propenamid og startmaterialer derav

Info

Publication number
NO20090137L
NO20090137L NO20090137A NO20090137A NO20090137L NO 20090137 L NO20090137 L NO 20090137L NO 20090137 A NO20090137 A NO 20090137A NO 20090137 A NO20090137 A NO 20090137A NO 20090137 L NO20090137 L NO 20090137L
Authority
NO
Norway
Prior art keywords
methyl
propenamide
hydroxy
phenyl
ethyl
Prior art date
Application number
NO20090137A
Other languages
English (en)
Other versions
NO341870B1 (no
Inventor
Joel Slade
Joginder S Bajwa
Murat Acemoglu
David Parker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090137(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20090137L publication Critical patent/NO20090137L/no
Publication of NO341870B1 publication Critical patent/NO341870B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

N-hydroksy-3444[[2^2-metyl4H-indolO-yl)etyl]amino]metyl]fenyl]-2E-2-propenamid og utgangsmaterialer derfor fremstilles ved nye syntesefremgangsmåter.
NO20090137A 2006-06-12 2009-01-09 Fremgangsmåte for fremstilling av N-hydroksy-3-[4-[[[2-(2-metyl-1H-indol-3-yl)etyl]amino]-metyl]fenyl]-2E-2-propenamid og utgangsmaterialer for denne NO341870B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80452706P 2006-06-12 2006-06-12
US86787806P 2006-11-30 2006-11-30
PCT/US2007/070564 WO2007146718A2 (en) 2006-06-12 2007-06-07 Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino] methyl]phenyl]-2e-2-propenamide and starting materials therefor

Publications (2)

Publication Number Publication Date
NO20090137L true NO20090137L (no) 2009-03-03
NO341870B1 NO341870B1 (no) 2018-02-12

Family

ID=38832681

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090137A NO341870B1 (no) 2006-06-12 2009-01-09 Fremgangsmåte for fremstilling av N-hydroksy-3-[4-[[[2-(2-metyl-1H-indol-3-yl)etyl]amino]-metyl]fenyl]-2E-2-propenamid og utgangsmaterialer for denne

Country Status (31)

Country Link
US (2) US20090306405A1 (no)
EP (2) EP2032533B8 (no)
JP (2) JP5431926B2 (no)
KR (2) KR101540194B1 (no)
CN (4) CN101466674A (no)
AR (1) AR061296A1 (no)
AU (1) AU2007257883B2 (no)
BR (1) BRPI0712847A2 (no)
CA (1) CA2653657C (no)
CL (2) CL2007001691A1 (no)
DK (1) DK2032533T3 (no)
EC (1) ECSP088978A (no)
ES (2) ES2553255T3 (no)
GT (1) GT200800282A (no)
HR (1) HRP20130798T1 (no)
IL (2) IL195211A (no)
IN (1) IN2015DN00910A (no)
JO (1) JO2900B1 (no)
MA (1) MA30513B1 (no)
MX (2) MX2008015898A (no)
MY (1) MY147576A (no)
NO (1) NO341870B1 (no)
NZ (1) NZ572707A (no)
PE (2) PE20080851A1 (no)
PL (1) PL2032533T3 (no)
PT (1) PT2032533E (no)
RU (1) RU2448090C2 (no)
TN (1) TNSN08507A1 (no)
TW (1) TWI395734B (no)
WO (1) WO2007146718A2 (no)
ZA (1) ZA200809490B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000004075A1 (it) * 2020-02-27 2021-08-27 Flamma Spa Processo per la preparazione di panobinostat

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB146260A (en) 1918-07-11 1921-08-11 Elektro Osmose Ag A process for preparing proteids charged with immune substances
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002055742A2 (en) 2001-01-09 2002-07-18 Novartis Ag Rapid method for screening compounds for in vivo activity
RU2311200C2 (ru) 2001-11-06 2007-11-27 Новартис Аг Комбинация ингибитора циклооксигеназы-2 и ингибитора гистондезацетилазы
MX2008015899A (es) * 2006-06-12 2009-04-01 Novartis Ag Procedimiento para hacer sales de n-hidroxi-3-[4-[[[2-(2-metil-1h- indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida.

Also Published As

Publication number Publication date
JP5809223B2 (ja) 2015-11-10
KR101493530B1 (ko) 2015-02-13
EP2032533B1 (en) 2013-04-03
AU2007257883A1 (en) 2007-12-21
CN103086944A (zh) 2013-05-08
IL195211A (en) 2014-08-31
NZ572707A (en) 2011-12-22
IL233836A (en) 2017-05-29
HK1126759A1 (en) 2009-09-11
IL195211A0 (en) 2009-08-03
IL233836A0 (en) 2014-09-30
CN102174008A (zh) 2011-09-07
DK2032533T3 (da) 2013-07-01
AR061296A1 (es) 2008-08-20
CA2653657A1 (en) 2007-12-21
IN2015DN00910A (no) 2015-07-10
ECSP088978A (es) 2009-01-30
JP5431926B2 (ja) 2014-03-05
KR101540194B1 (ko) 2015-07-28
CN102167678A (zh) 2011-08-31
BRPI0712847A2 (pt) 2012-08-07
PE20080851A1 (es) 2008-08-18
WO2007146718A3 (en) 2008-06-19
JP2009540008A (ja) 2009-11-19
RU2008151726A (ru) 2010-07-20
EP2032533B8 (en) 2013-12-11
HRP20130798T1 (en) 2013-09-30
TW200815345A (en) 2008-04-01
KR20140117703A (ko) 2014-10-07
ES2416286T3 (es) 2013-07-31
GT200800282A (es) 2009-03-09
NO341870B1 (no) 2018-02-12
US20090306405A1 (en) 2009-12-10
HK1162029A1 (en) 2012-08-17
TNSN08507A1 (en) 2010-04-14
JO2900B1 (en) 2015-09-15
EP2032533A2 (en) 2009-03-11
MX2008015898A (es) 2009-01-12
CL2007001691A1 (es) 2008-05-16
ZA200809490B (en) 2009-10-28
MY147576A (en) 2012-12-31
JP2014058532A (ja) 2014-04-03
RU2448090C2 (ru) 2012-04-20
KR20090015969A (ko) 2009-02-12
AU2007257883B2 (en) 2011-09-29
CA2653657C (en) 2015-10-27
ES2553255T3 (es) 2015-12-07
TWI395734B (zh) 2013-05-11
CN102167678B (zh) 2013-08-28
US8536346B2 (en) 2013-09-17
EP2394991B1 (en) 2015-09-23
CN101466674A (zh) 2009-06-24
EP2394991A1 (en) 2011-12-14
MX366213B (es) 2019-07-01
MA30513B1 (fr) 2009-06-01
US20120010418A1 (en) 2012-01-12
PE20120221A1 (es) 2012-03-21
PL2032533T3 (pl) 2013-08-30
PT2032533E (pt) 2013-06-28
CL2010000973A1 (es) 2011-07-01
WO2007146718A2 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
NO20090135L (no) Polymorfer av N-hydroksy-3-[4-[[[-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]2E-2-propenamid
NO20090136L (no) Fremgangsmate for fremstilling av salter av N-hydroksy-3-[4-[[[2-(2-metyl-1H-1ln-dol-3-yl)etyl]amino]metyl]fenyl]-2E-2-propenamid
NO20090128L (no) Salter av N-hydroksy-3-[4-[[[2-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]-2E-2-propenamid
NO20090137L (no) Fremgangsmate for fremstilling av N-hydroksy-3-[4-[[[2-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]-2E-2-propenamid og startmaterialer derav
UA95289C2 (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
ZA200809651B (en) Process for making salts of N-hydroxy-3[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
UA97243C2 (en) Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
HK1132509A (en) Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου
DOP2008000069A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.
CY1114470T1 (el) Διαδικασια για την παρασκευη ν- υδροξυ-3-ý4-ýýý2-(2-μεθυλο-1η-ινδολ-3- υλ) αιθυλο ¨αμινο¨ μεθυλο ¨φαινυλο¨-2ε-2- προπεναμιδιου και τα υλικα εναρξης αυτων
DOP2008000068A (es) Polimorfos de n-hidroxi-3[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: SECURA BIO, US

MM1K Lapsed by not paying the annual fees